Exclusive

Publication

Byline

Mint Explainer | US exits WHO: What it means for global health and America

New Delhi, Jan. 25 -- The US has formally withdrawn from the World Health Organization (WHO), a year after President Donald Trump signed an executive order to begin the process. The move deprives the... Read More


Sun Pharma gets DCGI nod to make generic version of Wegovy

New Delhi, Jan. 24 -- Sun Pharmaceutical Industries Ltd has received the Drugs Controller General of India's (DCGI) approval to make and market a generic version of semaglutide injection for weight ma... Read More


Syngene cuts guidance as key product loss weighs on growth

Mumbai, Jan. 23 -- Contract drug research and manufacturing firm Syngene International Ltd has lowered its full-year revenue guidance from mid-single digit growth to negative 2-3%, as destocking of a ... Read More


Sun Pharma gets nod to make generic Wegovy

Mumbai, Jan. 23 -- Sun Pharmaceutical Industries Ltd has received the Drugs Controller General of India's (DCGI) approval to make and market a generic version of semaglutide injection for weight manag... Read More


Zydus launches cancer biosimilar nivolumab at steep discount

MUMBAI, Jan. 22 -- Zydus Lifesciences has launched its biosimilar of anti-cancer drug nivolumab in India after receiving clearance from the Delhi High Court last week, pricing it at a fraction of the ... Read More


Dr Reddy's net profit beats estimates despite 14% dip, set for India semaglutide launch

New Delhi, Jan. 21 -- Hyderabad-based Dr Reddy's Laboratories beat street estimates in the third quarter, reporting revenue of Rs.8,726.8 crore and profit after tax (PAT) of Rs.1,210 crore, with stead... Read More


Pharma Q3 preview: Core business, India growth to offset Revlimid pain

New Delhi, Jan. 15 -- As India's pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of paten... Read More


Pharma Q3 preview: India growth, base business may offset US headwinds

New Delhi, Jan. 15 -- As India's pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of paten... Read More


Pee Safe raises $32 million from OrbiMed to accelerate expansion

New Delhi, Jan. 14 -- Pee Safe, a personal hygiene brand, plans to expand its offline and online presence after raising $32 million ( Rs.290 crore) from global healthcare-focused private equity firm O... Read More


The year Indian drug innovation bets started paying off

New Delhi, Jan. 6 -- Dear reader, as 2025, a year of global tumult and volatility, rolls by, Mint's reporters and columnists look around the corner on what is coming in 2026-to help you know what to e... Read More